Kortegaard Anne-Sofie, Rokkjær Rikke B, Harboe Hanne Marie H, Lund Sten, Andersen Anette, Bohl Mette
Steno Diabetes Center Aarhus, Aarhus University Hospital, Palle Juul-Jensens Boulevard 11, 8200 Aarhus N, Denmark.
Steno Diabetes Center Aarhus, Aarhus University Hospital, Palle Juul-Jensens Boulevard 11, 8200 Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200 Aarhus N, Denmark.
Eur J Intern Med. 2024 Oct;128:87-93. doi: 10.1016/j.ejim.2024.06.002. Epub 2024 Jun 8.
To assess diabetes-related emotional distress (DD) in emerging adults with type 1 diabetes (T1D) and assess a group-based intervention's impact.
To investigate DD we used data from the Problem Areas in Diabetes Questionnaire comprising 20 items (PAID-20). Furthermore, changes in the WHO Well-Being Index comprising five items (WHO-5) and glycated haemoglobin (HbA1c) were analysed. The intervention was evaluated using follow-up data from the emerging adults who participated.
From 2021 to 2023, we screened 180 emerging adults using PAID-20. DD (PAID-20≥30) was prevalent in 25.0 % (95 % CI 18.9; 32.0 %), and associated with the female sex, higher HbA1c and WHO-5 < 50. Continuous subcutaneous insulin infusion at baseline was associated with PAID-20<30. 21 individuals attended a group-based intervention. At one-week follow up PAID-20 was reduced (29.1 ± 15.4 vs. 41.3 ± 12.1 at baseline, p = 0.003), and at nine-twelve months' follow-up HbA1c was reduced (59.3 ± 15.3 mmol/mol vs. 68.0 ± 17.4 mmol/mol at baseline, p = 0.012).
This pilot study demonstrated that 25 % of the investigated emerging adults with T1D experienced DD (PAID-20≥30) associated with four clinical factors. We found a reduction in HbA1c and a short-term reduction in PAID-20 following the group-based intervention.
评估1型糖尿病(T1D)初显期成人的糖尿病相关情绪困扰(DD),并评估基于小组的干预措施的影响。
为调查DD,我们使用了糖尿病问题问卷(PAID-20)中的20项数据。此外,还分析了包含5项内容的世界卫生组织幸福指数(WHO-5)和糖化血红蛋白(HbA1c)的变化。使用参与研究的初显期成人的随访数据对干预措施进行评估。
2021年至2023年期间,我们使用PAID-20对180名初显期成人进行了筛查。DD(PAID-20≥30)的患病率为25.0%(95%可信区间18.9;32.0%),与女性、较高的HbA1c和WHO-5<50相关。基线时持续皮下胰岛素输注与PAID-20<30相关。21人参加了基于小组的干预。在一周随访时,PAID-20降低(基线时为41.3±12.1,随访时为29.1±15.4,p=0.003),在9至12个月随访时,HbA1c降低(基线时为68.0±17.4 mmol/mol,随访时为59.3±15.3 mmol/mol,p=0.012)。
这项初步研究表明,25%的被调查T1D初显期成人经历了与四个临床因素相关的DD(PAID-20≥30)。我们发现基于小组的干预后HbA1c降低,PAID-20短期内降低。